After Head Injury Drug Fails, Edge Merges with Immuno-Oncology Firm PDS

After Head Injury Drug Fails, Edge Merges with Immuno-Oncology Firm PDS

Source: 
Xconomy
snippet: 

An experimental head injury drug took Edge Therapeutics all the way to the public markets. But one failed clinical trial later and the company is now heading for the exits.